Drug Profile
Research programme: Hedgehog cell-signalling pathway inhibitors - MAX BioPharma
Alternative Names: Hedgehog signalling pathway antagonists - MAX BioPharma; Liver X receptor agonists - MAX BioPharma; Oxysterol LXR agonists - MAX BioPharmaLatest Information Update: 27 Mar 2023
Price :
$50
*
At a glance
- Originator MAX BioPharma
- Class Small molecules; Sterols
- Mechanism of Action Hedgehog cell-signalling pathway inhibitors; Liver X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple myeloma; Pancreatic cancer
Most Recent Events
- 27 Mar 2023 Preclinical development for Pancreatic cancer and Multiple myeloma is ongoing in USA (MAX Biopharma website, March 2023)
- 07 Oct 2013 Preclinical trials in Multiple myeloma in USA (unspecified route)
- 07 Oct 2013 Preclinical trials in Pancreatic cancer in USA (unspecified route)